Collegium Pharmaceutical (COLL) revenue breakdown
By product, Belbuca is the largest at 28% of fiscal 2025 revenue; Jornay PM grew fastest, 300% a year over 1 years.
Revenue by product
Fiscal years, as Collegium Pharmaceutical reports them in its 10-K filings; fiscal 2025 total $781M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Belbuca | — | — | — | — | $126M | $182M | $211M | $222M | 28% |
| Xtampza ER | $69M | $105M | $128M | $104M | $139M | $177M | $191M | $199M | 26% |
| Jornay PM | — | — | — | — | — | — | $37M | $149M | 19% |
| Nucynta IR | $130M | $118M | $116M | $102M | $112M | $108M | $101M | $115M | 15% |
| Nucynta ER | $81M | $74M | $66M | $71M | $72M | $83M | $76M | $81M | 10% |
| Symproic and other | — | — | — | — | $12M | $16M | $15M | $14M | 2% |
| Other | — | — | — | — | $2M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for COLL.
Open COLL in InvestinglyQuestions
Where does Collegium Pharmaceutical make its money?
In fiscal 2025, by product: Belbuca $222M, Xtampza ER $199M, Jornay PM $149M, Nucynta IR $115M, Nucynta ER $81M.
From Collegium Pharmaceutical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.